

ASX Announcement

13 September 2024

OncoSil Medical Continues Strong Market Penetration in Spain with 30th OncoSil™ Treatment

Sydney, Australia – 13 September 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce a significant milestone in its expansion in Spain, with the successful completion of the 30th treatment involving the OncoSil™ device. This treatment was carried out on 11 September 2024 at Hospital HM Sanchinarro, one of Spain’s leading cancer treatment centers.

Currently, 12 sites in Spain are actively using the OncoSil™ device, while another 4 sites have completed training and are ready to begin treatments. This expanding network demonstrates the company's strong progress in penetrating the addressable market in Spain, which continues to advance at a rapid pace.

OncoSil Medical looks forward to further expanding its presence in the European market and will continue to provide updates on its progress in Spain and beyond.

OncoSil Medical Managing Director & CEO Nigel Lange said: *“Reaching 30 treatments in Spain is a remarkable accomplishment and a testament to the growing recognition of OncoSil™ as an innovative treatment for pancreatic cancer. Spain has become one of our key markets in Europe, and we are proud to see such strong engagement from leading hospitals and clinics across the country.”*

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

| | | |
|--|--|---|
| Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043 | Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254 | Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699 |
|--|--|---|

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>